An Msh2 Conditional Knockout Mouse for Studying Intestinal Cancer and Testing Anticancer Agents

Gastroenterology

Volumn 138, Issue 3, 2010, Pages

  Kucherlapati, Melanie H ^a   Lee, Kyeryoung ^b   Nguyen, Andrew A ^a   Clark, Alan B ^c   Hou Jr , Harry ^b   Rosulek, Andrew ^a   Li, Hua ^b   Yang, Kan ^d   Fan, Kunhua ^d   Lipkin, Martin ^d   Bronson, Roderick T ^e,f   Jelicks, Linda ^b   Kunkel, Thomas A ^c   Kucherlapati, Raju ^a   Edelmann, Winfried ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d Department of Anesthesiology Weill Medical Center   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Mismatch Repair; Msh2; Tumorigenesis

Indexed keywords

APC PROTEIN; CISPLATIN; CRE RECOMBINASE; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OXALIPLATIN; PROTEIN MSH2; VILLIN;

ADENOMA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; EMBRYO; FEMALE; FIBROBLAST; GASTROINTESTINAL CARCINOMA; GENE DISRUPTION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; LOXP SITE; LYMPHOMA; MALE; MICROSATELLITE INSTABILITY; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; TRANSGENE; TUMOR VOLUME; WESTERN BLOTTING;

EID: 77249113263     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.11.009     Document Type: Article

References (37)

1. Fishel R., Lescoe M.K., Rao M.R., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (1993) 1027-1038
2. Lothe R.A., Peltomaki P., Meling G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53 (1993) 5849-5852
3. Marsischky G.T., Filosi N., Kane M.F., et al. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10 (1996) 407-420
4. de Wind N., Dekker M., Berns A., et al. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82 (1995) 321-330
5. Reitmair A.H., Schmits R., Ewel A., et al. MSH2-deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11 (1995) 64-70
6. Smits R., Hofland N., Edelmann W., et al. Somatic Apc mutations are selected upon their capacity to inactivate the β-catenin down-regulating activity. Genes Chromosomes Cancer 29 (2000) 229-239
7. Reitmair A.H., Cai J.C., Bjerknes M., et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 56 (1996) 2922-2926
8. Lee E.C., Yu D., Martinez de Velasco J., et al. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73 (2001) 56-65
9. Liu P., Jenkins N.A., and Copeland N.G. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 13 (2003) 476-484
10. Ioffe E., Liu Y., Bhaumik M., et al. WW6: an embryonic stem cell line with an inert genetic marker that can be traced in chimeras. Proc Natl Acad Sci U S A 92 (1995) 7357-7361
11. Rodriguez C.I., Buchholz F., Galloway J., et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25 (2000) 139-140
12. Lakso M., Pichel J.G., Gorman J.R., et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A 93 (1996) 5860-5865
13. el Marjou F., Janssen K.P., Chang B.H., et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004) 186-193
14. Thomas D.C., Umar A., and Kunkel T.A. Measurement of heteroduplex repair in human cell extracts. Methods: A companion to Methods Enzymol 7 (1995) 187-197
15. Thomas D.C., Roberts J.D., and Kunkel T.A. Heteroduplex repair in extracts of human HeLa cells. J Biol Chem 266 (1991) 3744-3751
16. Kabbarah O., Mallon M.A., Pfeifer J.D., et al. A panel of repeat markers for detection of microsatellite instability in murine tumors. Mol Carcinog 38 (2003) 155-159
17. Dietrich W.F., Miller J.C., Steen R.G., et al. A genetic map of the mouse with 4006 simple sequence length polymorphisms. Nat Genet 7 (1994) 220-245
18. Kuraguchi M., Edelmann W., Yang K., et al. Tumor-associated Apc mutations in Mlh1-/- Apc1638N mice reveal a mutational signature of Mlh1 deficiency. Oncogene 19 (2000) 5755-5763
19. Wei K., Clark A.B., Wong E., et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 17 (2003) 603-614
20. Andreutti-Zaugg C., Scott R.J., and Iggo R. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 57 (1997) 3288-3293
21. Avdievich E., Reiss C., Scherer S.J., et al. Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis. Proc Natl Acad Sci U S A 105 (2008) 4247-4252
22. Menko F.H., Kaspers G.L., Meijer G.A., et al. A homozygous MSH6 mutation in a child with cafe-au-lait spots, oligodendroglioma and rectal cancer. Fam Cancer 3 (2004) 123-127
23. Raevaara T.E., Gerdes A.M., Lonnqvist K.E., et al. HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. Genes Chromosomes Cancer 40 (2004) 261-265
24. Rey J.M., Noruzinia M., Brouillet J.P., et al. Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancer. Cancer Genet Cytogenet 155 (2004) 149-151
25. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
26. Kucherlapati M.H., Nguyen A.A., Bronson R.T., et al. Inactivation of conditional Rb by Villin-Cre leads to aggressive tumors outside the gastrointestinal tract. Cancer Res 66 (2006) 3576-3583
27. Kucherlapati M.H., Yang K., Fan K., et al. Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. Proc Natl Acad Sci U S A 105 (2008) 15493-15498
28. Hinoi T., Akyol A., Theisen B.K., et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67 (2007) 9721-9730
29. Lin D.P., Wang Y., Scherer S.J., et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 64 (2004) 517-522
30. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 61 (2001) 7369-7374
31. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
32. Yamada M., O'Regan E., Brown R., et al. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 25 (1997) 491-496
33. Stojic L., Brun R., and Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 3 (2004) 1091-1101
34. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
35. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1999) 123-131
36. Meyers M., Wagner M.W., Hwang H.S., et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61 (2001) 5193-5201
37. Tajima A., Hess M.T., Cabrera B.L., et al. The mismatch repair complex hMutS α recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127 (2004) 1678-1684